Imprimis Pharmaceuticals (NSDQ:IMMY) touted data today from a peer-reviewed study of patients who received its “dropless therapy” following cataract surgery.
The San Diego-based company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient non-compliance or dosing errors. The compounded formulations use Imprimis’ patent-pending SSP technology, which helps active pharmaceutical ingredients solubilize into a well-distributed particle suspension.
Get the full story at our sister site, Drug Delivery Business News.